Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet Therapy Among Patients With Ischemic Stroke
- 1 October 2013
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (7), 463-470
- https://doi.org/10.7326/0003-4819-159-7-201310010-00006
Abstract
Background: Dual-antiplatelet regimens for prevention of recurrent stroke promote antithrombotic effects but may increase the risk for hemorrhage. Purpose: To qualitatively and quantitatively examine the risk for recurrent stroke and intracranial hemorrhage (ICH) linked to long-term dual-and single-antiplatelet therapy among patients with ischemic stroke and transient ischemic attack. Data Sources: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials through March 2013 without language restrictions. Study Selection: The search identified 7 randomized, controlled trials that involved a total of 39 574 participants and reported recurrent stroke and ICH as outcome measures. Data Extraction: All data from eligible studies were independently abstracted by 2 investigators according to a standard protocol. Data Synthesis: Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0.89 [95% CI, 0.78 to 1.01]) or clopidogrel monotherapy (RR, 1.01 [CI, 0.93 to 1.08]). Risk for ICH did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (RR, 0.99 [CI, 0.70 to 1.42]) but was greater among patients receiving dual-antiplatelet therapy than among those receiving clopidogrel monotherapy (RR, 1.46 [CI, 1.17 to 1.82]). Limitation: Agents used in dual-and single-antiplatelet therapies varied across trials, and the relatively modest number of trials limited subgroup analysis. Conclusion: Compared with monotherapy, dual-antiplatelet therapy lasting more than 1 year after an index ischemic stroke or transient ischemic attack is not associated with a greater reduction in overall recurrent stroke risk. However, long-term dual-antiplatelet therapy is linked to higher risk for ICH than clopidogrel monotherapy in this patient population. Primary Funding Source: Chang Gung Memorial Hospital.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic StrokeStroke, 2013
- Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic strokeBMC Neurology, 2012
- Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic AttackStroke, 2012
- The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: A Randomized, Double-Blind, Controlled TrialCerebrovascular Diseases, 2011
- Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA TrialInternational Journal of Stroke, 2011
- Low risk of rebound events after a short course of clopidogrel in acute TIA or minor strokeNeurology, 2010
- Quality-Adjusted Life Expectancy (QALE) and Loss of QALE for Patients With Ischemic Stroke and Intracerebral HemorrhageStroke, 2010
- The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS)Health and Quality of Life Outcomes, 2010
- Six-Year Survival and Causes of Death among Stroke Patients in KoreaNeuroepidemiology, 2008
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008